Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study

November 6, 2007

AudioMedica News

00:00 /

Uwe Zeymer

REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
UWE ZEYMER, Herzzentrum Ludwigshafen, Germany
The glycoprotein 2B 3A antagonist eptifibatide has performed as well as standard abciximab therapy in patients receiving primary angioplasty for acute myocardial infarction. So according to Uwe Zeymer who presented findings on this it can be used in this setting just as it is already being used in elective PCI. Sarah Maxwell interviewed Dr Zeymer at the Orlando conference.

[audio:https://www.audiomedica.com/podcasting/cardio/071105UweZeymerPODCAST.mp3]

Tagged as:abciximab acute angioplasty antagonist cardiovascular myocardial therapies therapy uwe zeymer

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

May 28, 2020

Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...

Audio Cardiovascular

Competitive and Leisure Sports: Recommendations to Minimise Cardiovascular Risk

August 28, 2016

Atrial fibrillation is prevented by exercise and life-long endurance athletes do not face the same elevated risks of stroke and heart disease from...

Audio Cardiovascular

AudioMedica.com with MDFM: Novel oral anticoagulants: latest opinion from the ESC congress

October 3, 2013

AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of...

Cardiovascular

SAVOR-TIMI 53 study: saxagliptin had better glucose control than placebo but no cardiovascular benefit

September 22, 2013

AMSTERDAM — The SAVOR-TIMI 53 study in 16 000 patients has confirmed the efficacy of the DPP-4 inhibitor, saxagliptin, for controlling...

Cardiovascular

Novel oral anticoagulants: latest opinion from the ESC congress

September 22, 2013

AMSTERDAM—Whether triple anti-thrombotic therapy should be accepted as generally the optimal approach for treating patients at high risk of...

Cardiovascular

Young adults less likely to be diagnosed with hypertension than over 60s

December 31, 2012

AudioMedica News Young adults less likely to be diagnosed with hypertension than over 60s Play Episode Pause Episode Mute/Unmute Episode Rewind 10...

Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study

Further reading

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

Competitive and Leisure Sports: Recommendations to Minimise Cardiovascular Risk

AudioMedica.com with MDFM: Novel oral anticoagulants: latest opinion from the ESC congress

SAVOR-TIMI 53 study: saxagliptin had better glucose control than placebo but no cardiovascular benefit

Novel oral anticoagulants: latest opinion from the ESC congress

Young adults less likely to be diagnosed with hypertension than over 60s

Menu